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ABSTRACT
The objective of this study was to evaluate the activities of ciprofloxacin and levofloxacin in a murine
model of pneumonia caused by Klebsiella pneumoniae C2 (with altered GyrA, deficient in porins and
expressing active efflux of quinolones) and the transconjugant C2pMG252 derived from it and
expressing the qnrA1 determinant. MICs and MBCs of the two quinolones were determined according to
CLSI guidelines. Time-kill curves (at 1· and 4· MIC) were also performed to assess bactericidal activity.
An experimental model of pneumonia in mice was evaluated. Groups of 15 mice were infected with
either strain and treated with ciprofloxacin (80 mg ⁄kg ⁄day) or levofloxacin (100 mg ⁄ kg ⁄day). Control
non-treated animals were also evaluated. In the case of strain C2, log10 CFU ⁄ g of lung in non-treated
animals was 9.16 ± 2.16. This value was reduced to 3.53 ± 1.04 (p <0.001) and 3.38 ± 0.46 (p <0.001) in
animals treated with ciprofloxacin or levofloxacin, respectively. Percentages of surviving mice were
26.7% (control group) and 100% (both ciprofloxacin and levofloxacin; p <0.001 vs. controls). Bacterial
counts (log10 CFU ⁄g) in lungs of animals infected with strain C2pMG252 were 9.65 ± 2.49 in non-treated
animals and 7.74 ± 2.67 and 7.57 ± 3.84 for those treated with ciprofloxacin or levofloxacin, respectively
(p >0.05 vs. control group). Of non-treated animals infected with strain C2pMG252, 14.3% survived.
Ciprofloxacin and levofloxacin improved the survival in these mice (53.3% for both antimicrobials,
p 0.03). In conclusion, the expression of qnrA1 in K. pneumoniae with additional mechanisms of
resistance causes decreased efficacy of fluoroquinolones in a pneumonia model in mice.
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INTRODUCTION
Plasmid-mediated resistance to quinolones has
been described in Klebsiella pneumoniae, Escherichia
coli, Enterobacter spp. and other Enterobacteria-
ceae [1,2]. Three different mechanisms have been
involved, including proteins of the Qnr family
(QnrA,QnrB andQnrS) [3–10], an acetyltransferase
enzyme (AAC(6¢)-Ib-cr) affecting both some am-
inoglycosides and some fluoroquinolones [11],
and an active efflux pump (QepA) [12,13]. QnrA1
causes a moderate level of resistance by
protecting both DNA gyrase [14,15] and topo-
isomerase IV [16] from quinolones. Expression of
qnrA1 in organisms lacking other mechanisms of
resistance to quinolones rarely translates into
MICs corresponding to the resistant category,
but when this determinant is harboured by Gram-
negative bacteria with changes in topoisomerases,
decreased permeability and ⁄ or increased active
efflux, it may cause quinolone resistance [17].
Interestingly, most clinical isolates producing
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QnrA1 are more resistant to quinolones than
transconjugants obtained from them, indicating
that the former usually contain additional mech-
anisms of resistance to quinolones [3–11].
The in vivo activity of quinolones in the clinical
setting is related to their MIC values. Several
reports [18–21] indicate that in humans a 24-h
area under the serum concentration time curve
(AUC) ⁄MIC ratio of ‡25–30 for immuno-
competent patients or ‡100–125 for immuno-
compromised patients and a serum peak
concentration ⁄MIC ratio >8 are good indicators
of a favourable outcome of quinolone treatment. It
may be anticipated from these indexes that an
increase in the MIC of a quinolone (of even just a
few dilution steps, as induced by qnrA1) will have
a negative impact on its therapeutic efficacy.
In spite of the available knowledge on micro-
biological and epidemiological aspects related to
qnrA1 and other plasmid-mediated determinants
of quinolone resistance, there is little information
on its in vivo relevance as a factor contributing to
quinolone resistance. In this study, we have tested
the activities of two fluoroquinolones in an
experimental murine model of pneumonia caused
by two strains of K. pneumoniae (with altered
GyrA, deficient in porins and expressing active
efflux of quinolones) producing or not producing
QnrA1, respectively.
MATERIALS AND METHODS
Bacterial strains
K. pneumoniae C2 has been previously described [3,22,23]. It
lacks b-lactamases, does not produce porins OmpK35 and
OmpK36, contains a gyrA mutation responsible for a Ser83Phe
change in DNA-gyrase, and expresses active efflux of quinol-
ones. K. pneumoniae C2pMG252 is a transconjugant derived
from K. pneumoniae C2, containing the plasmid pMG252,
which codes for qnrA1 [2,3]. K. pneumoniae C2pMG252 does
not lose pMG252 upon repeated subculturing (up to nine
subcultures) in antimicrobial-free medium (data not shown).
Antimicrobial agents
Ciprofloxacin was from Bayer (Leverkusen, Germany) and
levofloxacin from Roussel Uclaf (Paris, France).
In vitro susceptibility testing and time-kill experiments
MICs of ciprofloxacin and levofloxacin for strains C2 and
C2pMG252 were determined by microdilution, according to
CLSI guidelines [24]. The activities of the two fluoroquinolones
were tested using two different inocula: 105 and 107 CFU ⁄mL.
MBCs were determined by subculturing, onto antimicrobial-
free Mueller–Hinton agar (Difco, Detroit, MI), 100-lL aliquots
from wells containing antimicrobial concentrations greater
than or equal to the MIC of the corresponding agent. Plates
were incubated at 35C for 48 h, and viable colonies were
counted. MBCs were determined as the concentration that
killed ‡99.9% of the initial inoculum.
Time-kill kinetic assays were conducted on Mueller–Hinton
broth at drug concentrations of 1· and 4· MIC. Antimicrobial
agent-free broth was evaluated in parallel as a control.
Cultures were incubated at 37C, without shaking. Viable
counts were determined by serial dilution at 0, 2, 4, 8 and 24 h
after adding the drug, and plating 100 lL of control or test
cultures or dilutions at the indicated times onto Mueller–
Hinton agar plates. Plates were incubated for 48 h, and after
colony counts, the log10 of viable cells (CFU ⁄mL) was
determined. The time needed to achieve a 3 log10 drop in
bacterial viability was also determined, as an index of
bactericidal activity.
Animals
Immunocompetent C57BL ⁄ 6 female mice weighing 14–16 g
were used. They were obtained from the Universidad de
Sevilla’s Facility, having a sanitary status of murine pathogen-
free. Animals were housed in regulation cages and given free
access to food and water. The use of the experimental
pneumonia model was approved by the Ethics Committee of
the Hospitales Universitarios Virgen del Rocı´o, Seville, Spain.
Drug pharmacokinetics
The plasma levels of ciprofloxacin and levofloxacin were
determined after the administration of a single intraperitoneal
dose of either antimicrobial. The dosage administered was
20 mg ⁄ kg for ciprofloxacin and25 mg ⁄ kg for levofloxacin.After
10, 15, 30, 60, 90, 120 and 150 min, bloodwas extracted from the
periorbital plexus in anaesthetisedmice, in groups of threemice
for every time-point. The plasmatic drug concentrations were
measured in triplicate by a bioassay method, using Staphylococ-
cus epidermidis ATCC 27626 as indicator strain. The intraday
and interday variations of the assays were 6.27 ± 1.45% and
5.96 ± 0.57% for ciprofloxacin, and 7.82 ± 10.11% and
7.18 ± 9.03% for levofloxacin. The linearity (r2) of the assay
was 0.96 ± 0.04 and 0.99 ± 0.07, respectively; and the lower
limits of detection were 0.9 lg ⁄L for both compounds. The
pharmacokinetic parameters (Cmax, mg ⁄L; AUC, mgÆh ⁄L; and
t1 ⁄ 2, h) were calculated using the PKCALC program [25].
Experimental pneumonia model in mice
A modification of the Esposito and Pennington model [26]
performed by our group [27] was used for the production of
pneumonia. The mice were anaesthetized by an intraperitoneal
injection of 5% sodium thiopental. They were suspended
vertically and the trachea was then cannulated with a blunt-
tipped metal needle. The feel of the needle tip against
the tracheal cartilage confirmed the intra-tracheal location.
A microlitre syringe (Hamilton Co., Reno, NV, USA) was used
for inoculation. After the inoculation, the mice remained in a
vertical position for 3 min and then in a 30positionuntil awake.
K. pneumoniae C2 and C2pMG252 were used in the exper-
imental pneumonia. The animals were inoculated with 50 lL
of the K. pneumoniae bacterial suspension, obtained through an
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18-h culture in trypticase soy broth (Becton-Dickinson Micro-
biology Systems) at 37C, mixed 1:1 with porcine mucin
diluted to 10% in saline solution (M-2378; Sigma Chemical Co.,
St Louis, MO, USA), with a final inoculum size of
c. 108 CFU ⁄mL.
Antimicrobial treatment
To evaluate the effectiveness of the different treatment regi-
mens, 50 mice were inoculated with strain C2 and 50 mice with
strain C2pMG252. Then, they were divided into three groups
receiving the following treatments for 72 h: control group (no
treatment, n = 20); ciprofloxacin, 80 mg ⁄kg ⁄day (20 mg ⁄kg at
8 and 14 h, and 40 mg ⁄ kg at 20 h) intraperitoneally (n = 15);
and levofloxacin, 100 mg ⁄ kg ⁄day (25 mg ⁄ kg at 8 and 14 h, and
50 mg ⁄ kg at 20 h) intraperitoneally (n = 15). The first dose of
every antibiotic was administered 4 h after inoculation. The
mice were observed for 72 h for mortality and the surviving
mice were killed, 4 h after the last dose in the treatment groups
and at the same time in the control group, by intraperitoneal
administration of 5% sodium thiopental (Braun Medical,
Barcelona, Spain). All the mice (dead and killed) were
analyzed immediately after death.
After the animals’ deaths, thoracotomy was carried out. The
heart and lungs were extracted together and the lungs were
later separated on a sterile Petri plate and weighed. The lungs
were processed for quantitative culture, after being homogen-
ised in 2 mL of sterile saline solution (Stomacher 80; Tekmar
Co., Cincinnati, OH, USA). After ten-fold dilution, aliquots of
100 lL were plated on Columbia sheep blood agar plates for
24 h at 37C. The results were expressed as mean ± SD of the
log CFU ⁄ g of lung.
Lung samples were processed for histological studies, in
five mice of each control group. The lungs were fixed with
10% formaldehyde for histopathological study. The lung
blocks were embedded in paraffin and cut into 4-lm-thick
sections. The slices included all the pulmonary lobes to be
studied by optical microscopy. They were processed according
to standard methods for haematoxylin–eosin, periodic
acid–Schiff, Gram’s, Masson’s Trichromic and silver reticulin
stains.
In order to confirm that ciprofloxacin and levofloxacin were
not toxic to the animals, groups of five non-infected mice were
given each antibiotic and they were observed for 72 h of
treatment.
Statistical analysis
The means of the log10 CFU ⁄g of tissue of the different
treatment groups were compared by ANOVA. If the difference
was significant, the comparison among treatment groups was
made using Dunnett and Tukey–Kramer post-hoc tests.
Frequency of survival was analyzed by Fisher’s exact test.
The statistical package SPSS version 12.0 (SPSS Inc., Chicago,
IL, USA) was used.
RESULTS
MICs and MBCs
The MICs for the tested strains are summarised in
Table 1. qnrA1 increased the MICs of ciprofloxacin
or levofloxacin four to eight times. A similar
inoculum effect was noted for the two quinolones
against the two tested strains (MICs >128 mg ⁄L
when a 107 CFU ⁄mL inoculum was used; data not
shown).
The MBCs of the two fluoroquinolones were
the same as the corresponding MICs, except for
ciprofloxacin against strain C2 and levofloxacin
against strain C2 pMG252, where the MBC was
one dilution higher (Table 1).
Time-kill curves
The results of the bacterial killing assays are
presented in Fig. 1. When using 4· MIC, cipro-
floxacin and levofloxacin caused reductions in
viable strain C2 at 4 h of 4.52 and 4.63 log10,
respectively. Ciprofloxacin maintained this activ-
ity for up to 24 h, but bacterial regrowth was
noted with levofloxacin at 24 h. For strain
C2pMG252, the reductions in viable organisms
caused by ciprofloxacin and levofloxacin at
4· MIC were 3.972 and 3.98 log10 at 4 h; cipro-
floxacin maintained this activity during the 24-h
time period of the assay, but again regrowth was
noted with levofloxacin at 24 h. Similar results
were observed when the two compounds were
tested at 1· MIC, except that bacterial regrowth
was noted with ciprofloxacin at 24 h for strain
C2pMG252, and that regrowth was noted, begin-
ning at 8 h, with levofloxacin for strain C2. The
time needed to achieve a 3 log10 drop in bacterial
viability was 2 h for strain C2 (except with
levofloxacin at 1· MIC at 4 h) and 4 h for strain
C2pMG252.
Pharmacokinetic studies
The pharmacokinetic ⁄pharmacodynamic (P ⁄K)
parameters of each antimicrobial drug (Cmax,
Cmax ⁄MIC, t1 ⁄ 2, AUC, and AUC0–24 ⁄MIC) are
shown in Table 2. The AUC0–24 ⁄MIC ratio of the
Table 1. MICs and MBCs of ciprofloxacin and levofloxa-
cin for Klebsiella pneumoniae C2 and K. pneumoniae
C2pMG252
Strain Compound MIC (mg ⁄L) MBC (mg ⁄L)
K. pneumoniae C2 Ciprofloxacin 0.5 1
Levofloxacin 0.5 0.5
K. pneumoniae C2pMG252 Ciprofloxacin 4 4
Levofloxacin 2 4
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antimicrobials used was higher than 30 for strain
C2, but remained below 7 for strain C2pMG252.
The Cmax ⁄MIC ratio was higher than 15 for strain
C2 and <3 for strain C2pMG252.
Histopathological studies
The mice inoculated with strains C2 and
C2pMG252 showed alterations compatible with
acute pneumonia. They presented acute inflam-
mation, characterized by diffuse and ⁄ or focal
effects on all lobes, with mild-to-severe inflam-
matory infiltration of polymorphonuclear cells,
sometimes forming segmentary abscesses, and
mild-to-moderate infiltration of alveolar macro-
phages; Gram-negative bacterial colonies and
alveolar haemorrhagic areas were also observed
(results not shown).
Therapeutic efficacy in experimental pneumonia
Survival rates, and bacterial counts in the lungs, of
the different animal groups are shown in Table 3.
When considering animals treated with ciproflox-
acin or levofloxacin, the survival rate was higher in
the groups infected with strain C2 (100% with
both drugs) than in those infected with strain
C2pMG252 (53.3% with both drugs, p 0.03). Sim-
ilarly, considering clearance of bacteria from the
lungs, the two quinolones were more efficient in
the groups infected with strain C2 than in those
infected with strain C2pMG252 (p <0.001).
DISCUSSION
The results from this study suggest that production
of QnrA1 may be of clinical relevance when this
determinant is expressed inK. pneumoniae contain-
ing additional mechanisms of resistance to quinol-
ones. It has been shown that when these additional
mechanisms are not present, bacteria producing
QnrA1 remain susceptible to the bactericidal effect
of fluoroquinolones [28]. In this study, MBCs were
higher, in absolute terms, for the strain producing
QnrA1 than for the strain not producing it (but still
containing other mechanisms of resistance to qui-
nolones); this probably reflects higherMICs for the
QnrA1-producing strain, as the MBC ⁄MIC ratios
were not much different for the strains with and
without QnrA1. The results of the time-kill assays
indicate that the two quinolones assayed main-
tained bactericidal activity against the two tested
strains, but bacterial regrowth was noted after 8 h
in strain C2pMG252 (in all cases except with
ciprofloxacin at 4· MIC) and in strain C2 with
levofloxacin. The results from the animal model
Table 2. Pharmacokinetic ⁄pharmacodynamic parameters of ciprofloxacin and levofloxacin for Klebsiella pneumoniae C2
and K. pneumoniae C2pMG252
Antimicrobial agent Cmax (mg ⁄L) t1 ⁄ 2 (h) AUC (mgÆh ⁄L)
Cmax ⁄MIC AUC0–24 ⁄MIC
K. pneumoniae C2 K. pneumoniae C2pMG252 K. pneumoniae C2 K. pneumoniae C2pMG252
Ciprofloxacin (20 mg ⁄ kg) 11.57 ± 2.3 0.38 6.56 23.14 2.89 52.48 6.56
Levofloxacin (25 mg ⁄ kg) 7.89 ± 0.8 0.39 3.98 15.78 1.97 31.84 3.98
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Fig. 1. Viable counts of Klebsiella pneumoniae C2 and
K. pneumoniae C2pMG252 in time-kill assays with cipro-
floxacin (CIP) and levofloxacin (LVX) at 1·MIC or 4·MIC,
in comparison with an antibiotic-free control.
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support the notion that production of QnrA1
interferes with the in vivo activity of the two
fluoroquinolones. This is also supported by our
recent observation that expression of qnrA1
increases the mutant prevention concentration of
quinolones and readily increases the selection of
resistant sub-populations containing mutations in
the gyrA and parC genes [29].
The current breakpoints for fluroquinolones
and Enterobacteriaceae set by the CLSI categorize
some organisms harbouring mutations or genetic
elements related to quinolone resistance as sus-
ceptible [30]. Much lower PK ⁄PD breakpoints,
predicting efficacy of, and prevention of resis-
tance to, fluoroquinolones have been proposed
[31]. The values defined by EUCAST (available
at: http://www.srga.org/eucastwt/MICTAB/
MICquinolones.htm), which are more similar to
these PK ⁄PD breakpoints, may be more clinically
relevant.
A study [32] on patients infected with K. pneu-
moniae producing TEM-52 and for which the MIC
of ciprofloxacin was 0.38 mg ⁄L (susceptible
according to CLSI) indicates that treatment with
ciprofloxacin was associated with a partial
response or with treatment failure, probably
because of the low ratio between serum drug
concentrations and MICs in this study. In a rat
granuloma pounch model, 40 mg ⁄ kg of ciproflox-
acin resulted in therapeutic efficacy when consid-
ering a susceptible K. pneumoniae strain (MIC of
ciprofloxacin: 0.06 mg ⁄L), while efficacy against a
strain with an MIC of 0.5 mg ⁄L was achieved
only with a 200 mg ⁄ kg dose, indicating the
contribution of the decreased susceptibility of
the latter strain and, correspondingly, of the
PK ⁄PD parameters [33]. In contrast, we have
observed that both ciprofloxacin and levofloxacin
were efficacious in mice infected with a K. pneu-
moniae strain harboring a GyrA change, loss of
porins and an active efflux of quinolones for
which the MIC of ciprofloxacin was 0.5 mg ⁄L,
which may be explained by the improved phar-
macodynamic parameters achieved in our study.
It has been reported that the AUC0–24 ⁄MIC
ratio required for a bacteriostatic effect with
quinolones is about 35 and that an AUC ⁄MIC
value of ‡100 was associated with almost no
mortality [16]. In the case of experimental pneu-
monia caused by K. pneumoniae in mice, a static
effect was reached with an AUC0–24 ⁄MIC ratio of
43 and a killing effect was observed when this
ratio was 63 [34]. In the present study, a bacteri-
cidal effect was achieved with all the treatments
in mice infected with K. pneumoniae C2, in spite of
an AUC0–24 ⁄MIC ratio between 31 and 52, and the
survival rates were 100% with both ciprofloxacin
and levofloxacin. The fact that in the mice infected
with K. pneumoniae C2pMG252, with an AUC0–
24 ⁄MIC ratio of <7, there was no reduction in the
bacterial concentration in the lungs and the
survival diminished to 53% supports the conclu-
sion that an AUC0–24 ⁄MIC ratio of >30 may be
sufficient for the treatment of severe experimental
infections caused by K. pneumoniae.
In conclusion, the results from this study
indicate that the production of QnrA1 in K. pneu-
moniae with additional mechanisms of resistance
causes decreased efficacy of fluoroquinolones in a
pneumonia model in mice.
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Table 3. Effect of antibiotic therapy on the survival rates of mice and on the clearance of Klebsiella pneumoniae C2 and
K. pneumoniae C2pMG252 from their lungs
Treatment
Dosage
(mg ⁄kg ⁄day)
K. pneumoniae C2 K. pneumoniae C2pMG252
N Survival (%)
Log CFU ⁄ g of
lung, X ± SD N Survival (%)
Log CFU ⁄ g of
lung, X ± SD
Control 15 4 (26.7) 9.16 ± 2.16 15 2 (13.3) 9.65 ± 2.49
Ciprofloxacin 80 15 15 (100)a,b 3.53 ± 1.04a,c 15 8 (53.3)d 7.74 ± 2.67
Levofloxacin 100 15 15 (100)a,b 3.38 ± 0.46a,c 15 8 (53.3)d 7.57 ± 3.84
N, number of animals tested; X, mean value.
ap <0.001 as compared with the control group.
bp 0.003 as compared with the respective groups infected with K. pneumoniae C2pMG252.
cp <0.001 as compared with the respective groups infected with K. pneumoniae C2pMG252.
dp 0.03 as compared with the control group.
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